Fundz

Who to call at KIORA PHARMACEUTICALS, and when

Fundz watches for the moments KIORA PHARMACEUTICALS starts buying, and tells you who to reach.

  • An alert the day KIORA PHARMACEUTICALS raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at KIORA PHARMACEUTICALS, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at KIORA PHARMACEUTICALS. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Kiora Pharmaceuticals Enters Exclusive License Agreement with Senju Pharmaceutical for KIO-401

Oct 29, 2026

Contract Type

licensing

EncinitasHealthcare

Description

Kiora Pharmaceuticals has signed an Exclusive License Agreement with Senju Pharmaceutical to license KIO-401, a late-stage neuroprotective drug. The agreement grants Kiora exclusive rights to develop and commercialize the drug worldwide, except for specific countries. Kiora will handle the drug's development and regulatory filings at its own expense, with milestone payments tied to successful outcomes.

Company Information

Company

KIORA PHARMACEUTICALS

Location

332 ENCINITAS BOULEVARD

Encinitas, California, United States

About

Kiora Pharmaceuticals, Inc. (Kiora) is an ophthalmic specialty pharmaceutical company that develops therapies for the treatment of different types of eye diseases. Publicly-traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision.

Related People

Brian
Senior decision-maker at this company
••••••••@••••••••

See Brian's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for KIORA PHARMACEUTICALS's next move

Learn about Strategic plan

KIORA PHARMACEUTICALS signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.